Working in silos, change will not occur. WBC convenes with our Partners, Champions, and Sponsors to move faster together toward our action initiative goals.
Join us for Our Annual Action for Impact Summit!
WBC’s Annual Action for Impact Summit unites thousands of attendees on a fully interactive platform, enabling participants to network, connect, and exchange ideas, innovations, and impact in real time.
WOMEN CEO REPORT
Rachel E. Haurwitz, Ph.D., is the CEO of Caribou Biosciences, Inc., a biotechnology company specializing in CRISPR-based gene editing technologies. Dr. Haurwitzs leadership is characterized by her commitment to advancing cutting-edge scientific research and developing innovative gene-editing therapies. With extensive experience in biotechnology and genetic research, she has played a key role in guiding Caribou Biosciences through critical stages of research and development. Her vision includes leveraging CRISPR technology to address complex medical challenges and improve patient outcomes. Under her guidance, Caribou Biosciences continues to make significant strides in advancing gene-editing technologies and contributing to breakthroughs in biomedical research.
